The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Systemic Lupus Erythematosus
Interventions
- DRUG: M5049 low dose
- DRUG: M5049 medium dose
- DRUG: M5049 high dose
- DRUG: Placebo
Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany